PROGNOSTIC SIGNIFICANCE OF SST2 IN HEART FAILURE WITH REDUCED EJECTION FRACTION, A BIOMARKER OF CARDIOVASCULAR MORTALITY AND REHOSPITALIZATION.

Soluble Suppression of Tumorigenesis 2 (sST2) has emerged as a valuable prognostic biomarker for CHF, offering advantages over NT-proBNP due to its independence from confounding factors such as renal function and atrial rhythm. Elevated Soluble Suppression of Tumorigenesis 2 (sST2) levels are strongly correlated with increased mortality, hospitalizations, and adverse outcomes. While baseline Soluble Suppression of Tumorigenesis 2 (sST2) levels provide meaningful insights into disease severity, short-term changes are less indicative of prognosis. Integrating Soluble Suppression of Tumorigenesis 2 (sST2) into routine clinical practice could improve CHF management by enabling early identification of high-risk patients and guiding personalized treatment strategies.